What Is the Highest Dose of Wegovy for Weight Loss?

How the Wegovy dose ladder works in practice

Wegovy's licensed titration schedule is a genuine escalation, not a formality. The starting 0.25 mg dose is there to let your body adjust; nausea and other gastrointestinal effects are most noticeable in the early weeks, and jumping straight to a higher dose would make them far worse for most people. From 0.25 mg, the standard pathway moves to 0.5 mg, then 1.0 mg, then 1.7 mg, and then 2.4 mg, with roughly a month at each level, and you can read more about what the doses of Wegovy for weight loss look like at each stage on our Wegovy doses overview.

For most people, 2.4 mg is where treatment settles. If you've been wondering whether 2.4 mg is the highest dose of Wegovy, the answer depends on your clinical picture, since the newly approved 7.2 mg is assessed by your prescriber based on how much weight you've lost, how well you've tolerated the medicine so far, and whether your BMI meets the 30-or-above threshold the single-dose 7.2 mg pen is licensed for. No prescriber should push a patient up the ladder before they're ready, and none should leave a patient at a dose that isn't working when a higher one might be appropriate.

The NHS's semaglutide medicines page outlines the titration schedule and what to expect at each step, worth reading alongside any conversation with your prescriber.

What the evidence actually says about 7.2 mg versus 2.4 mg

The jump from 2.4 mg to 7.2 mg isn't cosmetic. Studies at the higher dose reported around 20.7% average weight loss over 72 weeks, compared with approximately 15% at 2.4 mg in the STEP 1 trial. That's a meaningful clinical difference, and it's part of why the MHRA approved the higher dose in the first place.

Understanding what the highest mg of Wegovy is becomes genuinely useful context if you're weighing up your options on our weight loss treatments page, particularly when comparing Wegovy at 7.2 mg with tirzepatide (Mounjaro) at its highest strength, since semaglutide activates a single GLP-1 receptor pathway while tirzepatide targets both GIP and GLP-1 receptors. Which produces better results for a specific person can't be predicted from population averages alone.

The 7.2 mg pen approved in April 2026 is auto-dosing, with a built-in covered needle that locks after use, a practical step forward for self-injection. Availability of specific dose formats is something to confirm at your consultation, since stock and supply can vary.

Who can actually reach the highest dose of Wegovy

The 7.2 mg single-dose pen carries a specific licensing condition: it is approved for adults with a BMI of 30 or above. It is not licensed for people with a lower BMI who might otherwise qualify for 2.4 mg under the standard weight-related-condition pathway, and it is not approved for Wegovy's cardiovascular indication. Your prescriber will check this before any move upward.

There's also the question of tolerance. Some people reach 2.4 mg and find the side-effect profile manageable; others find gastrointestinal effects significant enough to stay at 1.7 mg long term. Going to 7.2 mg when 2.4 mg is already causing persistent nausea isn't a sensible trade-off, and a responsible prescriber won't recommend it. The semaglutide highest dose page covers the eligibility picture in more depth if you want the full detail.

NICE's recommendation for semaglutide (Wegovy) (published under NICE technology appraisal TA875) applies to adults with at least one weight-related comorbidity and a BMI of 35 or above in NHS settings (lower thresholds apply for some ethnic backgrounds). Private prescribing follows the licensed SmPC criteria, which are broader, but the clinical judgement required is the same either way.

What this means for your next step

If you're currently on Wegovy and wondering whether 7.2 mg is something you should be working towards, that conversation belongs with your prescriber, who knows your history. If you're not yet on treatment and trying to understand what the dose ceiling looks like before you start, the short answer is that the journey matters as much as the destination: the highest dose of Wegovy is available, licensed, and supported by solid evidence, but you reach it through a supervised escalation, not by starting there.

A full overview of Wegovy covers the medicine from first principles if you'd like broader context before speaking to anyone. And if you're closer to a decision, a free consultation with a prescriber at our weight loss treatments page is the clearest next step, a real clinician reviews your answers the same day, not an automated queue.